At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,633 enrolled
Drug / intervention
Lasmiditan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
In Brief
A Phase 3 clinical trial evaluating Lasmiditan and Placebo for Migraine. Completed, enrolled 1,633 participants across 141 sites in 17 countries.
Detailed Summary
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesAustria, Belgium, China, Czechia, Denmark, France, Germany, Hungary, India, Italy, Mexico, Netherlands, Russia, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartJun 2019
Primary CompletionJun 2020
Study CompletionJul 2021
TodayJul 2026
First PostedSep 14, 2018
Enrollment StartJun 24, 2019
Primary CompletionJun 12, 2020
Study CompletionJul 8, 2021
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.8 years ago
Interventions
Lasmiditandrug
Administered orally.
Placebodrug
Administered orally.